**ASEAN Joint Assessments Procedure for Pharmaceutical Products**

**Information for applicants**

**Definition**

Joint assessments are a formal procedure in which the same[[1]](#footnote-2) application is simultaneously[[2]](#footnote-3) submitted to all participating ASEAN National Medicines Regulatory Authorities (NRAs). Assessment work is then carried out together by all participating NRAs and a joint assessment report is prepared. At the end of the process, the final decision on the application is then taken, within established time lines, by each individual NRA through their normal decision-making process based on the joint report and, where applicable, nationally-relevant considerations.

**Product eligibility criteria**

The JA procedure will initially adopt the following eligibility criteria:

a) medicines for treatment of priority diseases;

b) products already approved by a reference NRA, prequalified by WHO-PQP, or assessed

through special regulatory pathways such as EU Article 58 or US-FDA tentative approval;

c) products manufactured in a PIC/S-GMP compliant site (documentary verification only,

no inspections foreseen).

Each Notice (see below) inviting expressions of interest will indicate which reference NRAs are accepted for each specific product.

**Overall description of the procedure**

The JA procedure entails the following steps:

1. The first step is the publication of Notices of Invitation to Express Interest. At appropriate intervals, and on the basis of the agreement reached by the JACG, participating ASEAN NRAs will post Notices of Invitation to Express Interest on their web sites inviting applicants to express their interest in submitting applications through the JA procedure. Notices will mention the following elements of information:
   * 1. which medicinal products are eligible for the JA procedure within a specified time frame;
     2. which ASEAN NRAs are tentatively participating for which products and which NRA is the Lead NRA for each product;
     3. time frame for submitting Expressions of Interest and any other relevant aspect of the procedure.
2. In situations of high public health concern, as determined by ASEAN NRAs, selected manufacturers may be directly invited to submit specified products for assessment under the JA procedure without publication of Notices for expressions of interest.
3. Applicants express their interest in participating using the standard form [AEOI](#_Annex_1) (Annex 1) and, when necessary, form [AEOI1](#_Annex_1a) (Annex 1a). By submitting an expression of interest, applicants undertake to share the same information with all participating NRAs on all aspects of quality, safety and efficacy of the specified medicinal products along with information on variations implemented and/or planned.
4. Lead NRA seeks concurrence and confirmation from all participating NRAs to accept Expression of Interest. If a sufficient number of participating NRAs concur, Lead NRA requests applicant to submit a full application (see point 5 below) and a copy of a letter authorising reference NRA (see model in annex [2a](#_Annex_2a)) or WHO-PQP (see model in annex [2b](#_Annex_2b))to share confidential information on the product and its assessment and inspections’ reports. Applicants must submit applications to all participating NRAs as announced in the Lead NRA request.
5. Applications must comply with the following aspects:

a) the technical application dossier must include the same technical information as that submitted to reference NRA or WHO-PQP;

b) the technical part of the dossier in ACTD or ICH-CTD format shall be provided in electronic form to be uploaded to a dedicated, secure web site set up by WHO; only participating NRAs will be able to access and download the dossiers;

c) administrative part of dossier specific to each participating NRA requirements will be submitted directly to each participating authority;

d) fees as required by each participating NRA will be paid according to normal national procedures.

1. The administrative part of the dossier, including fees when applicable, shall be submitted individually to all participating NRAs following locally applicable procedures. The technical part of the dossier shall be uploaded to a dedicated, secure web site managed by WHO (uploading instructions will be provided). Review of applications will start only after all participating NRAs have received the application(s) and related documentation and have considered it accepted for assessment.
2. The Lead NRA coordinates and facilitates the implementation of the procedure and acts as ‘rapporteur’. The Lead NRA will undertake the following steps (further addressed below and shown in flowchart next page):

a) verify that all participating NRAs have received the administrative part of application dossier;

b) verify that applicant’s submission is complete and receive confirmation by participating NRAs;

c) request applicant to provide missing documentation, if applicable;

d) ensure that exchange of letters for sharing documentation (see below) is completed;

e) request reference NRA to share confidential information and assessment and inspections’ reports;

f) lead the assessment of application dossier, coordinate the preparation of draft assessment report  and circulate to participating NRAs (this is done by sharing tasks among all participating NRAs, as feasible);

g) receive comments by participating NRAs about draft assessment report and, if applicable, need to request additional information from applicant;

h) receive and circulate feedback from applicant, if applicable;

i) set date for assessors from participating NRAs to participate in JA session;

j) coordinate with WHO and/or expert(s) from reference NRA for participation in JA session.

1. An exchange of formal agreement letters takes place, facilitated by WHO, between participating NRAs and either reference NRA or WHO-PQ. The exchange of letters addresses the following matters:
   1. participating NRAs convey to reference NRA/PQP their willingness to implement JA for a specific product;
   2. participating NRAs request access to information and commit to comply with confidentiality requirements;

If part of the information contained in the application dossier or in the reference NRA/PQ documentation to be shared does not belong to the applicant or to reference NRA/PQ, separate confidentiality commitments will have to be signed.

1. There could be situations in which a product proposed for JA is already authorized for marketing in one or more AMS. In these cases the NRA that has already approved the product decides if it wishes to participate in the JA anyway. The applicant must act according to the NRA decision and submit a full application according to the JA procedure. The outcome of the JA may result in no change, in a variation to the existing marketing authorization, or in a new marketing authorization.
2. Participating NRAs notify the Lead NRA that application and reference documentation from reference NRA or WHO-PQP have been received. When all NRAs have received the necessary documentation and notifications have been received, Lead NRA tentatively plans a JA session to take place within an agreed time line that can be different for different products. During the time leading to the JA session, the Lead NRA coordinates the preparation of a draft assessment report and shares it with all participating NRAs. NRAs notify the Lead NRA about their observations, if any, on the documentation. Observations may entail requesting additional documentation from the applicant. In this case, the Lead NRA will ensure that all observations have been received and then notify the applicant as required. The time frame is suspended until response is received from the applicant addressing the observations raised.
3. After the feedback from the applicant has been received the Lead NRA shares it with all participating NRAs and coordinates the preparation of a draft joint assessment report. If all participating NRA concur with the conclusions stated in the draft report and deem unnecessary to raise further matters, then the report is formally transmitted to all NRAs for national decision-making. If one or more NRAs deem necessary a face-to-face discussion, the Lead NRA organizes a JA session with support from WHO.
4. At the request of participating NRAs through the Lead NRA, WHO will facilitate the participation of one or more senior assessors from a reference NRA or WHO-PQP in a JA session.
5. A JA session is a technical meeting attended by two designated assessors (or more if funds permit) from each participating NRA. The session is assisted, when requested, by senior assessors provided by reference NRA and/or WHO. Purpose of the JA session is to review and discuss all aspects of the application, clarify technical issues, address diverging opinions, and prepare a joint assessment report. A JA session is expected to last up to four working days. At the end of the JA session, participants take the joint assessment report to their own NRA for inclusion in the national decision-making process.
6. JA reports are confidential documents belonging to the participating NRAs. After receiving a JA report, each participating NRA is expected to take a decision on the application at their earliest decision-making meeting.

**Sharing of JA documentation among AMS**

An ASEAN NRA who has not participated in a JA procedure may receive an application for a product that has gone through a JA procedure after this has been finalized. This NRA may request another ASEAN NRA or the ASEAN Secretariat to share the relevant joint assessment report and may decide to rely on such report for its own national decision, if applicable legislation permits. When such situations arise, concerned applicants will be asked to sign a consent letter to permit such sharing of information.

Steps of JA process

JACG receives proposals for candidate products and publishes list based on discussion among NRAs

Lead NRA requests applicant to submit required documentation to participating NRAs

NRAs review administrative part of dossier and confirm to Lead NRAS that is in order

NRAs deem JA meeting unnecessary

Joint assessment report submitted to participating NRAs for final decision

Lead NRA organizes JA session to finalize joint assessment report discussing with other NRAs, WHO and reference NRA experts, as appropriate.

Applicants send to lead NRA Expression of Interest to submit mentioning product and reference NRA.

Lead NRA seeks concurrence of participating NRAs for accepting Expression of Interest.

NRAs exchange letters with reference NRA and obtain assessment report

Assessment starts (**T0**)

Lead NRA consolidates questions from participating NRAs and shares with applicant. Clock stop (**T1**)

Lead NRA prepares draft joint assessment report and shares with participating NRAs

Lead NRA receives response from applicant and shares with participating NRAs. Clock restart (**T2**)

NRAs deem JA meeting necessary

# Annex 1

**Expression of applicant’s interest for the submission of an application for the ASEAN Joint Assessment Procedure**

The undersigned Applicant expresses its interest to submit an application in the framework of the ASEAN Joint Assessment Procedure to all participating[[3]](#footnote-4) ASEAN NRAs based on the following details:

### Applicant details:

Name: (“the Applicant”)

Address:

E-mail:

Phone:

### Product details:

INN(s):

Dosage form and strength:

Packaging:

Detailed[[4]](#footnote-5) address of manufacturing site(s):

Brand name, if applicable:

### Reference approval[[5]](#footnote-6) details:

Reference NRA:

Marketing authorization number:

Date of approval (dd/mm/yyyy):

Date of latest revision[[6]](#footnote-7), if applicable (dd/mm/yyyy):

Marketing authorization holder:

WHO prequalification reference number:

Date of prequalification (dd/mm/yyyy):

WHO prequalification holder:

The Applicant confirms that the information and documentation provided in conjunction with the present Expression of Interest is true and correct, that the pharmaceutical product submitted for JA assessment is the same[[7]](#footnote-8)as the reference approval product and that the technical part of the information is the same[[8]](#footnote-9)as that submitted to reference approval NRA or WHO Prequalification Programme (WHO/PQP). Non-essential differences[[9]](#footnote-10)from the information submitted to WHO/PQP, are the following:

The Applicant:

1. undertakes to adhere to, and collaborate with the participating ASEAN NRAs, reference NRA/ WHO/PQP in line with the JA Procedure; and

2. authorizes the reference NRA/WHO/PQP[[10]](#footnote-11)to provide participating ASEAN NRAs confidential access to the following information and documentation and to freely discuss the same with participating ASEAN NRAs: a) the full assessment and inspection outcomes (reports); b) information and documentation on subsequent variations as well as information and documentation on any actions taken by the reference NRA/WHO/PQP after approval of the Product. To this end, the Applicant submits copy of the consent letter sent to the reference NRA or WHO/PQP.

As regards sharing the outcomes of assessments and inspections, only data owned by the applicant are shared. Sharing of any other data is subject to a separate additional agreement by the respective data owners.

3. authorizes the participating ASEAN NRAs to freely share and discuss all registration and product related information provided by the Applicant with the reference NRA or WHO/PQP, subject to the obligations of confidentiality and restrictions on use as contained in the relevant agreements and undertakings.

**☐** The applicant is not the reference NRA marketing authorization or WHO prequalification holder. An authorization letter from relevant holder is attached.

### For the Applicant

Signature:

Name:

Title:

Place:

Date (dd/mm/yyyy):

# Annex 1a

**Model authorization letter to be used if the applicant is not the holder of the reference NRA marketing authorization or WHO prequalification.**

A separate letter for each participating ASEAN NRA should be provided along with the Expression of Interest. A copy should be provided to the reference NRA or to WHO/PQP, as applicable.

This is to confirm that\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (*applicant name*) submitting application for the ASEAN Joint Assessment Procedure for product \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ approved by \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ with authorization number \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, is acting for, or pursuant to rights derived from \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (*name of reference NRA marketing authorization holder or WHO prequalification holder*) and that \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (*name of reference NRA marketing authorization holder or WHO prequalification holder*) agrees with the application for the Joint Assessment procedure in the concerned ASEAN countries.

For\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (*name of reference NRA marketing authorization holder or WHO prequalification holder*) :

Signature

Name

Title

Date

# Annex 2a

# Marketing authorization holder gives consent to reference NRA to share confidential information with ASEAN NRA for Joint Assessment Procedure

The marketing authorization holder hereby consents to \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (*name of reference NRA*) providing the following information and documentation to \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_(*name and address of ASEAN NRA*) to be used in conjunction with the ASEAN Joint Assessment procedure applied to the product described below, and to freely discuss product-related matters with the aforesaid ASEAN NRA:

* the full assessment and inspections’ reports;
* information and documentation on subsequent variations (as defined in the *WHO guidelines on variations to a prequalified product*, WHO Technical Report Series, No. 981, and any updates thereto), as well as information and documentation on any actions taken by \_\_\_\_\_\_\_\_\_\_\_\_\_ (*reference NRA*) after product approval;
* all other data, reports, information and documentation that are in possession of by \_\_\_\_\_\_\_\_\_\_\_\_\_ (*reference NRA*) and are necessary for the ASEAN Joint Assessment procedure.

As regards sharing the outcomes of assessments and inspections, only data owned by the marketing authorization holder are shared. Sharing of any other data is subject to additional agreement of the data owners concerned.[[11]](#footnote-12)

### Product details:

INN(s):

Dosage form and strength:

Packaging:

Detailed[[12]](#footnote-13) address of manufacturing site(s):

Brand name, if applicable:

### Reference approval details:

Reference NRA :

Marketing authorization number:

Date of approval (dd/mm/yyyy):

Date of latest revision[[13]](#footnote-14), if applicable (dd/mm/yyyy):

### Marketing authorization holder:

### Applicant details:

Applicant:

Address:

Email:

Phone:

For the marketing authorization holder

Signature:

Name:

Title:

Place:

Date (dd/mm/yyyy):

# Annex 2b

# WHO prequalification holder gives consent to WHO PQP to share confidential information with ASEAN NRA for Joint Assessment Procedure

The WHO prequalification holder hereby consents to WHO/PQP providing the following information and documentation to \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_(*name and address of ASEAN NRA*) to be used in conjunction with the ASEAN Joint Assessment procedure applied to the product described below, and to freely discuss product-related matters with the aforesaid ASEAN NRA:

* the full WHO/PQP assessment and inspections’ reports;
* information and documentation on subsequent variations (as defined in the *WHO guidelines on variations to a prequalified product*, WHO Technical Report Series, No. 981, and any updates thereto), as well as information and documentation on any actions taken by WHO/PQP post-prequalification of the Product.
* all such data, reports, information and documentation that are necessary for the ASEAN Joint Assessment procedure.

As regards sharing the outcomes of assessments and inspections, only data owned by the WHO prequalification holder are shared. Sharing of any other data is subject to additional agreement of the data owners concerned.[[14]](#footnote-15)

### Product details:

INN(s):

Dosage form and strength:

Packaging:

Detailed[[15]](#footnote-16) address of manufacturing site(s):

Brand name, if applicable:

### WHO prequalification details:

WHO prequalification reference number:

Date of prequalification (dd/mm/yyyy):

Date of requalification (if applicable):

WHO prequalification holder:

### Applicant details:

Applicant:

Address:

Email:

Phone:

For the WHO prequalification holder

Signature:

Name:

Title:

Place:

Date (dd/mm/yyyy):

1. Same application refers to the technical content of the application; national administrative parts remain different. [↑](#footnote-ref-2)
2. Simultaneously refers to the fact that JA process will not start until applications are received in all participating NRAs. [↑](#footnote-ref-3)
3. Names of participating NRAs for each specific eligible product(s) are mentioned in the Notice of Invitation to Express Interest. [↑](#footnote-ref-4)
4. Address of manufacturing sites must be detailed enough to identify the exact site. If more than one site is referred to, there should be brief mention of manufacturing phase(s) conducted at each site. [↑](#footnote-ref-5)
5. Accepted reference approvals are mentioned in the Notice of Invitation to Express Interest. [↑](#footnote-ref-6)
6. Revision refers to renewal, major variation, or other relevant regulatory decision. [↑](#footnote-ref-7)
7. Same pharmaceutical product means: same product dossier, same manufacturing chain, processes and control of materials, same API and FPP specifications and same essential elements of product information. [↑](#footnote-ref-8)
8. Technical data included in the dossier must be the same. There may be country-specific differences in administrative data. Additional technical data can be provided (e.g. bioequivalence with a country-specific comparator). [↑](#footnote-ref-9)
9. Non-essential differences include differences in administrative information, brand name, name of applicant, format of product information, level of detail of product information, labelling of internal and external packaging, and language of product information. [↑](#footnote-ref-10)
10. If the applicant for national registration is not the same as the WHO prequalification holder, then the authorization to WHO/PQP must be provided by the WHO prequalification holder or their legal representative. [↑](#footnote-ref-11)
11. If certain data do not belong to the WHO prequalification holder, the WHO prequalification holder specifies such data in an annex to this declaration of consent. If applicable, the WHO Prequalification holder will submit letters issued by data owns authorizing the use of the data in the ASEAN Joint Assessment procedure. [↑](#footnote-ref-12)
12. Address of manufacturing sites must be detailed enough to identify the exact site. If more than one site is referred to, there should be brief mention of manufacturing phase(s) conducted at each site. [↑](#footnote-ref-13)
13. Revision refers to renewal, major variation, or other relevant regulatory decision. [↑](#footnote-ref-14)
14. If certain data do not belong to the WHO prequalification holder, the WHO prequalification holder specifies such data in an annex to this declaration of consent. If applicable, the WHO Prequalification holder will submit letters issued by data owns authorizing the use of the data in the ASEAN Joint Assessment procedure. [↑](#footnote-ref-15)
15. Address of manufacturing sites must be detailed enough to identify the exact site. If more than one site is referred to, there should be brief mention of manufacturing phase(s) conducted at each site. [↑](#footnote-ref-16)